Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study-Reference-Cited by-同舟云学术

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

Published:2010-07-17 Issue:11 Volume:24 Page:1697-1707
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Martinez Esteban,Larrousse María,Llibre Josep M,Gutierrez Felix,Saumoy Maria,Antela Antonio,Knobel Hernando,Murillas Javier,Berenguer Juan,Pich Judit,Pérez Ignacio,Gatell José M

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference20 articles.

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection;Palella;N Engl J Med,1998

2. Principles and practice of HIV-protease inhibitor pharmacoenhancement;Moyle;HIV Med,2001

3. Class of antiretroviral drugs and the risk of myocardial infarction.;N Engl J Med,2007

4. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects;Hsu;Antimicrob Agents Chemother,1997

5. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations;Shafran;HIV Med,2005

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic steatosis after switching to integrase inhibitor-based regimens does not parallel short-term weight gain;AIDS;2023-10-26

2. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study;Frontiers in Cellular and Infection Microbiology;2023-06-26

3. Integrase Strand Transfer Inhibitor Use in Children with Perinatal HIV-1 Infection: A Narrative Review;AIDS Research and Human Retroviruses;2023-01-06

4. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China;JAIDS Journal of Acquired Immune Deficiency Syndromes;2022-10-01

5. Response to Commentary: Long-term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens;Frontiers in Immunology;2022-06-03